PRGO.TA - Perrigo Company plc

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
16,560.00
+520.00 (+3.24%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close16,040.00
Open16,180.00
Bid16,540.00 x 7100
Ask16,560.00 x 29700
Day's Range15,760.00 - 16,560.00
52 Week Range13,730.00 - 28,300.00
Volume181,614
Avg. Volume132,517
Market Cap22.92B
Beta (3Y Monthly)1.40
PE Ratio (TTM)25,915.49
EPS (TTM)0.64
Earnings DateN/A
Forward Dividend & Yield2.96 (1.85%)
Ex-Dividend Date2019-08-29
1y Target Est86.00
  • Barrons.com

    The 6 Worst Health-Care Stocks So Far This Month

    For health care investors this August, things could have been worse. But the past few weeks have been downright disastrous for some stocks.

  • PetIQ, Inc. (PETQ) Q2 2019 Earnings Call Transcript
    Motley Fool

    PetIQ, Inc. (PETQ) Q2 2019 Earnings Call Transcript

    PETQ earnings call for the period ending June, 30, 2019.

  • Perrigo (PRGO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Perrigo (PRGO) Q2 2019 Earnings Call Transcript

    PRGO earnings call for the period ending June 30, 2019.

  • TheStreet.com

    Perrigo Beats Second-Quarter Estimates but Stock Tumbles

    Perrigo is falling despite beating Wall Street's second-quarter earnings and revenue expectations.

  • Benzinga

    Perrigo Reports Q2 Earnings, Reaffirms Guidance

    Perrigo Co (NYSE: PRGO) reported second-quarter earnings of 86 cents per share, which beat the analyst consensus estimate of 79 cents by 8.86%. The company reported quarterly sales of $1.127 billion, which missed the analyst consensus estimate of $1.13 billion by 0.27%.

  • MarketWatch

    Perrigo's stock surges after profit and revenue decline less than expected, outlook affirmed

    Shares of Perrigo Co. surged 6.0% in premarket trading Thursday, after the over-the-counter health and wellness products company reported second-quarter profit and revenue that beat expectations, and affirmed its full-year outlook. Net income fell to $9 million, or 7 cents a share, from $36 million, or 26 cents a share, in the year-ago period. Excluding non-recurring items, adjusted EPS fell to 86 cents from $1.22, above the FactSet consensus of 79 cents. Sales declined 3.1% to $1.15 billion but topped the FactSet consensus of $1.13 billion, as consumer self-care America sales fell 2.5%, consumer self-care international sales declined 8.5% and prescription pharmaceuticals sales rose 3.4%. The company affirmed its 2019 adjusted EPS outlook of $3.75 to $4.05. The stock has run up 30.3% year to date through Wednesday, while the S&P 500 has gained 15.0%.

  • Perrigo Company plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation
    PR Newswire

    Perrigo Company plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation

    DUBLIN , Aug. 8, 2019 /PRNewswire/ -- GAAP ("reported") net sales were $1.15 billion , reflecting a 3% decline versus the prior year period. Non-GAAP ("adjusted") net sales increased ...

  • PR Newswire

    Perrigo Announces Resignation Of Jeffrey C. Smith From Its Board Of Directors

    TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products™", today announced that Jeffrey C. Smith, Managing Member, Chief Executive Officer, and Chief Investment Officer of Starboard Value LP, who has been a director since 2017, has resigned from Perrigo's Board of Directors effective August 7, 2019. "It is with mixed emotions that I leave the Board of Directors of Perrigo. "We are fortunate to have recruited a world-class leader in Murray Kessler who has quickly assembled an outstanding management team and repositioned Perrigo as a leading self-care company with numerous opportunities for growth and improved efficiency.

  • Benzinga

    Q2 Earnings Preview For Perrigo

    Perrigo Co (NYSE: PRGO ) releases its next round of earnings this Thursday, August 8. Get the latest predictions in Benzinga's essential guide to the company's Q2 earnings report. Earnings and Revenue ...

  • Perrigo Announces Quarterly Dividend
    PR Newswire

    Perrigo Announces Quarterly Dividend

    TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Announces Second Quarter Calendar Year 2019 Earnings Date
    PR Newswire

    Perrigo Announces Second Quarter Calendar Year 2019 Earnings Date

    TASE: PRGO), today announced that it will release its second quarter calendar year 2019 financial results on Thursday, August 8, 2019. The Company will host a conference call beginning at 8 a.m. (EDT).

  • Perrigo Completes Divestiture of Animal Health Business for $185 Million
    PR Newswire

    Perrigo Completes Divestiture of Animal Health Business for $185 Million

    TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (PETQ) for $185 million. Perrigo CEO and President Murray S. Kessler stated, "Completing the divestiture of the Animal Health business is an important step in the transformation of Perrigo into a consumer-focused self-care company.

  • GlobeNewswire

    PetIQ, Inc. Completes Acquisition of Perrigo Animal Health

    EAGLE, Idaho, July 08, 2019 -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced effective today, it has.

  • Perrigo Announces FDA Final Approval and Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel
    PR Newswire

    Perrigo Announces FDA Final Approval and Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel

    TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug Application ("ANDA") referencing Metrogel-Vaginal® (metronidazole vaginal gel 0.75%).  Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days and anticipates launching this product immediately thereafter. The product is manufactured by Perrigo and was developed through its partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. Perrigo Executive Vice President and President Rx Pharmaceuticals, Sharon Kochan stated, "This launch exemplifies Perrigo's commitment to developing and launching products within the extended topicals category.

  • Benzinga

    Perrigo Adjusts Guidance After Acquiring Ranir Global For $750M

    Perrigo Company (NYSE: PRGO ) has acquired Ranir Global Holdings, a supplier of oral self-care products for $750 million in cash. Perrigo also adjusted its FY2019 earnings guidance, from $3.75-$4.05 including ...

  • PR Newswire

    Perrigo Completes Acquisition Of Ranir, Raises Guidance

    - Advances transformation to a consumer-focused, self-care company - Raises 2019 non-GAAP ("adjusted") diluted EPS guidance to between $3.75 - $4.05 (1), which includes accretion of $0.10 from ...

  • Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%
    PR Newswire

    Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%

    TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) referencing Voltaren® Gel, 1% (diclofenac sodium topical gel, 1%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days. Perrigo will manufacture diclofenac sodium topical gel 1% in its plant in Israel.

  • Reuters

    US STOCKS-Wall St falls as weak economic data triggers growth worries

    U.S. stocks fell on Wednesday, as a clutch of weak economic data from the United States and China sparked worries of slowing global growth against the backdrop of a bitter trade dispute that has roiled financial markets. Domestic data showed retail sales unexpectedly fell in April as households cut back on purchases of motor vehicles and a range of other goods, and another report showed declining output of cars and machinery led to a surprise fall in U.S. factory production for April. Meanwhile data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on the country to roll out more stimulus.

  • Reuters

    US STOCKS-Wall St set to open lower after weak retail sales data

    Wall Street was set to open lower on Wednesday, as a surprise fall in domestic retail sales and underwhelming data from China raised growth concerns, while investors waited for more developments on the U.S.-China trade dispute. Government data showed U.S. retail sales unexpectedly fell in April as motor vehicle purchases slumped, while data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on Beijing to roll out more stimulus. "The U.S. retail sales report is clearly disappointing.

  • TheStreet.com

    Perrigo Buys Oral Care Company Ranir for $750 Million as Part of New Strategy

    was gaining more than 5% Thursday after announcing the all-cash acquisition of privately-held Ranir Global Holdings in a deal valued at $750 million. Ranir is the largest private label oral care company in the world, according to Perrigo, with a portfolio of more than 300 oral care products including toothbrush heads and whitening strips. "The addition of Ranir to the Perrigo family illustrates a key component of our new strategy, accelerating growth by pursuing adjacent self-care categories.

  • Perrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day
    PR Newswire

    Perrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day

    Chief Executive Officer and President Murray S. Kessler, along with several key members of his leadership team, will share the Company's strategic plan, vision, and financial objectives while introducing their priorities for transforming Perrigo from a healthcare company to a consumer self-care company. Kessler commented, "We have begun the process of transformation to recapture what we call 'The Perrigo Advantage'. The team has been hard at work during my first six months as CEO, analyzing our challenges and most importantly, building actionable plans to reinvent the company.

  • PR Newswire

    Global Oral Care Leader Ranir® Agrees to be Acquired by Leading Global Self-Care Company Perrigo

    Combines Two Consumer-Focused Self-Care Companies Dedicated to Meeting Customer Needs; Expands Ability to Deliver Millions of Affordable Healthy Smiles Worldwide GRAND RAPIDS, Mich. , May 9, 2019 /PRNewswire/ ...

  • Perrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products
    PR Newswire

    Perrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products

    DUBLIN, May 9, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced that it has reached a definitive agreement to purchase privately-held Ranir Global Holdings LLC ("Ranir") in a transaction valued at $750 million on a cash-free, debt-free basis, or approximately $685 million net of cash tax benefits on a present value basis. Ranir is the largest private label oral care company globally, with a comprehensive portfolio of 300+ highly customized oral care solutions including power toothbrush heads, power toothbrush handles, whitening strips, manual toothbrushes, floss, dentures and travel kits that it sells into over 50 countries worldwide.

  • PetIQ, Inc. (PETQ) Q1 2019 Earnings Call Transcript
    Motley Fool

    PetIQ, Inc. (PETQ) Q1 2019 Earnings Call Transcript

    PETQ earnings call for the period ending March 31, 2019.